Y M Geurts, S I M Neppelenbroek, B M P Aleman, C P M Janus, A D G Krol, D J van Spronsen, W J Plattel, J M Roesink, K M S Verschueren, J M Zijlstra, H R Koene, M R Nijziel, E C Schimmel, E de Jongh, F Ong, L C J Te Boome, R S van Rijn, L H Böhmer, B D P Ta, H P J Visser, E F M Posthuma, Y M Bilgin, K Muller, D van Kampen, C So-Osman, J S P Vermaat, R J de Weijer, M J Kersten, F E van Leeuwen, M Schaapveld
BACKGROUND: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. METHODS: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012...
February 12, 2024: ESMO Open